Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer: The SWIss Venous ThromboEmbolism Registry (SWIVTER) II
In patients with acute cancer-associated thrombosis, current consensus guidelines recommend anticoagulation therapy for an indefinite duration or until the cancer is resolved. Among 1,247 patients with acute venous thromboembolism (VTE) enrolled in the prospective Swiss Venous Thromboembolism Regist...
Gespeichert in:
| Veröffentlicht in: | Thrombosis and haemostasis 2011-06, Vol.105 (6), p.962-967 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 967 |
|---|---|
| container_issue | 6 |
| container_start_page | 962 |
| container_title | Thrombosis and haemostasis |
| container_volume | 105 |
| creator | SPIRK, David UGI, Jörg KUCHER, Nils KORTE, Wolfgang HUSMANN, Marc HAYOZ, Daniel BALDI, Thomas FRAUCHIGER, Beat BANYAI, Martin AUJESKY, Drahomir BAUMGARTNER, Iris |
| description | In patients with acute cancer-associated thrombosis, current consensus guidelines recommend anticoagulation therapy for an indefinite duration or until the cancer is resolved. Among 1,247 patients with acute venous thromboembolism (VTE) enrolled in the prospective Swiss Venous Thromboembolism Registry (SWIVTER) II from 18 hospitals, 315 (25%) had cancer of whom 179 (57%) had metastatic disease, 159 (50%) ongoing or recent chemotherapy, 83 (26%) prior cancer surgery, and 63 (20%) recurrent VTE. Long-term anticoagulation treatment for >12 months was more often planned in patients with versus without cancer (47% vs. 19%; p |
| doi_str_mv | 10.1160/TH11-01-0002 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1160_TH11_01_0002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21475778</sourcerecordid><originalsourceid>FETCH-LOGICAL-c245t-dac019ccd0e69acbb7186489b007525ad56fb2f78a317299c187de11d7b64e003</originalsourceid><addsrcrecordid>eNpFkEFLwzAYQIMobk5vniUXQcHql6xNWm8yphsMhFmnt5Km6VZZm5Gkyv6NP9XMbQpfSA4vj-QhdE7glhAGd-mIkAD8ANAD1KUR4wGLk_dD1IV-CAGjYdRBJ9Z-ABAWJtEx6lAS8ojzuIu-J7qZB06ZGovGVVKLebsUrtINdkYJV6vG4VIbLGTrFP5UjW4tdguj61wrv5aVrXHV4JW_5FmLvyq38K7i96Bbh6VopDL3OF0o_PI2thbPtpZ0axnuLVM1r6wza3zlsVk6nF7j8fgUHZViadXZbu-h18dhOhgFk-en8eBhEkj_PxcUQgJJpCxAsUTIPOckZmGc5AA8opEoIlbmtOSx6BNOk0SSmBeKkILnLFQA_R662Xql0dYaVWYrU9XCrDMC2SZ0tgmdgR8f2uMXW3zV5rUq_uB9WQ9c7gBhpViWxleo7D8XUv9uGvV_AIm6iGE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer: The SWIss Venous ThromboEmbolism Registry (SWIVTER) II</title><source>MEDLINE</source><source>Thieme Connect Journals</source><creator>SPIRK, David ; UGI, Jörg ; KUCHER, Nils ; KORTE, Wolfgang ; HUSMANN, Marc ; HAYOZ, Daniel ; BALDI, Thomas ; FRAUCHIGER, Beat ; BANYAI, Martin ; AUJESKY, Drahomir ; BAUMGARTNER, Iris</creator><creatorcontrib>SPIRK, David ; UGI, Jörg ; KUCHER, Nils ; KORTE, Wolfgang ; HUSMANN, Marc ; HAYOZ, Daniel ; BALDI, Thomas ; FRAUCHIGER, Beat ; BANYAI, Martin ; AUJESKY, Drahomir ; BAUMGARTNER, Iris</creatorcontrib><description>In patients with acute cancer-associated thrombosis, current consensus guidelines recommend anticoagulation therapy for an indefinite duration or until the cancer is resolved. Among 1,247 patients with acute venous thromboembolism (VTE) enrolled in the prospective Swiss Venous Thromboembolism Registry (SWIVTER) II from 18 hospitals, 315 (25%) had cancer of whom 179 (57%) had metastatic disease, 159 (50%) ongoing or recent chemotherapy, 83 (26%) prior cancer surgery, and 63 (20%) recurrent VTE. Long-term anticoagulation treatment for >12 months was more often planned in patients with versus without cancer (47% vs. 19%; p<0.001), with recurrent cancer-associated versus first cancer-associated VTE (70% vs. 41%; p<0.001), and with metastatic versus non-metastatic cancer (59% vs. 31%; p<0.001). In patients with cancer, recurrent VTE (OR 3.46; 95%CI 1.83-6.53), metastatic disease (OR 3.04; 95%CI 1.86-4.97), and the absence of an acute infection (OR 3.55; 95%CI 1.65-7.65) were independently associated with the intention to maintain anticoagulation for >12 months. In conclusion, long-term anticoagulation treatment for more than 12 months was planned in less than half of the cancer patients with acute VTE. The low rates of long-term anticoagulation in cancer patients with a first episode of VTE and in patients with non-metastatic cancer require particular attention.</description><identifier>ISSN: 0340-6245</identifier><identifier>EISSN: 2567-689X</identifier><identifier>DOI: 10.1160/TH11-01-0002</identifier><identifier>PMID: 21475778</identifier><identifier>CODEN: THHADQ</identifier><language>eng</language><publisher>Stuttgart: Schattauer</publisher><subject>Acute Disease ; Adult ; Aged ; Aged, 80 and over ; Anticoagulants - administration & dosage ; Anticoagulants - adverse effects ; Biological and medical sciences ; Blood coagulation. Blood cells ; Clinical Protocols ; Disease Progression ; Fundamental and applied biological sciences. Psychology ; Hematologic and hematopoietic diseases ; Heparin, Low-Molecular-Weight - administration & dosage ; Heparin, Low-Molecular-Weight - adverse effects ; Humans ; Medical sciences ; Molecular and cellular biology ; Neoplasm Metastasis ; Neoplasms - complications ; Neoplasms - drug therapy ; Neoplasms - physiopathology ; Neoplasms - surgery ; Platelet diseases and coagulopathies ; Recurrence ; Switzerland ; Time Factors ; Venous Thromboembolism - drug therapy ; Venous Thromboembolism - etiology ; Venous Thromboembolism - physiopathology ; Venous Thromboembolism - surgery</subject><ispartof>Thrombosis and haemostasis, 2011-06, Vol.105 (6), p.962-967</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c245t-dac019ccd0e69acbb7186489b007525ad56fb2f78a317299c187de11d7b64e003</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24224525$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21475778$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SPIRK, David</creatorcontrib><creatorcontrib>UGI, Jörg</creatorcontrib><creatorcontrib>KUCHER, Nils</creatorcontrib><creatorcontrib>KORTE, Wolfgang</creatorcontrib><creatorcontrib>HUSMANN, Marc</creatorcontrib><creatorcontrib>HAYOZ, Daniel</creatorcontrib><creatorcontrib>BALDI, Thomas</creatorcontrib><creatorcontrib>FRAUCHIGER, Beat</creatorcontrib><creatorcontrib>BANYAI, Martin</creatorcontrib><creatorcontrib>AUJESKY, Drahomir</creatorcontrib><creatorcontrib>BAUMGARTNER, Iris</creatorcontrib><title>Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer: The SWIss Venous ThromboEmbolism Registry (SWIVTER) II</title><title>Thrombosis and haemostasis</title><addtitle>Thromb Haemost</addtitle><description>In patients with acute cancer-associated thrombosis, current consensus guidelines recommend anticoagulation therapy for an indefinite duration or until the cancer is resolved. Among 1,247 patients with acute venous thromboembolism (VTE) enrolled in the prospective Swiss Venous Thromboembolism Registry (SWIVTER) II from 18 hospitals, 315 (25%) had cancer of whom 179 (57%) had metastatic disease, 159 (50%) ongoing or recent chemotherapy, 83 (26%) prior cancer surgery, and 63 (20%) recurrent VTE. Long-term anticoagulation treatment for >12 months was more often planned in patients with versus without cancer (47% vs. 19%; p<0.001), with recurrent cancer-associated versus first cancer-associated VTE (70% vs. 41%; p<0.001), and with metastatic versus non-metastatic cancer (59% vs. 31%; p<0.001). In patients with cancer, recurrent VTE (OR 3.46; 95%CI 1.83-6.53), metastatic disease (OR 3.04; 95%CI 1.86-4.97), and the absence of an acute infection (OR 3.55; 95%CI 1.65-7.65) were independently associated with the intention to maintain anticoagulation for >12 months. In conclusion, long-term anticoagulation treatment for more than 12 months was planned in less than half of the cancer patients with acute VTE. The low rates of long-term anticoagulation in cancer patients with a first episode of VTE and in patients with non-metastatic cancer require particular attention.</description><subject>Acute Disease</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticoagulants - administration & dosage</subject><subject>Anticoagulants - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Blood coagulation. Blood cells</subject><subject>Clinical Protocols</subject><subject>Disease Progression</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Heparin, Low-Molecular-Weight - administration & dosage</subject><subject>Heparin, Low-Molecular-Weight - adverse effects</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Molecular and cellular biology</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasms - complications</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - physiopathology</subject><subject>Neoplasms - surgery</subject><subject>Platelet diseases and coagulopathies</subject><subject>Recurrence</subject><subject>Switzerland</subject><subject>Time Factors</subject><subject>Venous Thromboembolism - drug therapy</subject><subject>Venous Thromboembolism - etiology</subject><subject>Venous Thromboembolism - physiopathology</subject><subject>Venous Thromboembolism - surgery</subject><issn>0340-6245</issn><issn>2567-689X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEFLwzAYQIMobk5vniUXQcHql6xNWm8yphsMhFmnt5Km6VZZm5Gkyv6NP9XMbQpfSA4vj-QhdE7glhAGd-mIkAD8ANAD1KUR4wGLk_dD1IV-CAGjYdRBJ9Z-ABAWJtEx6lAS8ojzuIu-J7qZB06ZGovGVVKLebsUrtINdkYJV6vG4VIbLGTrFP5UjW4tdguj61wrv5aVrXHV4JW_5FmLvyq38K7i96Bbh6VopDL3OF0o_PI2thbPtpZ0axnuLVM1r6wza3zlsVk6nF7j8fgUHZViadXZbu-h18dhOhgFk-en8eBhEkj_PxcUQgJJpCxAsUTIPOckZmGc5AA8opEoIlbmtOSx6BNOk0SSmBeKkILnLFQA_R662Xql0dYaVWYrU9XCrDMC2SZ0tgmdgR8f2uMXW3zV5rUq_uB9WQ9c7gBhpViWxleo7D8XUv9uGvV_AIm6iGE</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>SPIRK, David</creator><creator>UGI, Jörg</creator><creator>KUCHER, Nils</creator><creator>KORTE, Wolfgang</creator><creator>HUSMANN, Marc</creator><creator>HAYOZ, Daniel</creator><creator>BALDI, Thomas</creator><creator>FRAUCHIGER, Beat</creator><creator>BANYAI, Martin</creator><creator>AUJESKY, Drahomir</creator><creator>BAUMGARTNER, Iris</creator><general>Schattauer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20110601</creationdate><title>Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer: The SWIss Venous ThromboEmbolism Registry (SWIVTER) II</title><author>SPIRK, David ; UGI, Jörg ; KUCHER, Nils ; KORTE, Wolfgang ; HUSMANN, Marc ; HAYOZ, Daniel ; BALDI, Thomas ; FRAUCHIGER, Beat ; BANYAI, Martin ; AUJESKY, Drahomir ; BAUMGARTNER, Iris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c245t-dac019ccd0e69acbb7186489b007525ad56fb2f78a317299c187de11d7b64e003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Acute Disease</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticoagulants - administration & dosage</topic><topic>Anticoagulants - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Blood coagulation. Blood cells</topic><topic>Clinical Protocols</topic><topic>Disease Progression</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Heparin, Low-Molecular-Weight - administration & dosage</topic><topic>Heparin, Low-Molecular-Weight - adverse effects</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Molecular and cellular biology</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasms - complications</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - physiopathology</topic><topic>Neoplasms - surgery</topic><topic>Platelet diseases and coagulopathies</topic><topic>Recurrence</topic><topic>Switzerland</topic><topic>Time Factors</topic><topic>Venous Thromboembolism - drug therapy</topic><topic>Venous Thromboembolism - etiology</topic><topic>Venous Thromboembolism - physiopathology</topic><topic>Venous Thromboembolism - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SPIRK, David</creatorcontrib><creatorcontrib>UGI, Jörg</creatorcontrib><creatorcontrib>KUCHER, Nils</creatorcontrib><creatorcontrib>KORTE, Wolfgang</creatorcontrib><creatorcontrib>HUSMANN, Marc</creatorcontrib><creatorcontrib>HAYOZ, Daniel</creatorcontrib><creatorcontrib>BALDI, Thomas</creatorcontrib><creatorcontrib>FRAUCHIGER, Beat</creatorcontrib><creatorcontrib>BANYAI, Martin</creatorcontrib><creatorcontrib>AUJESKY, Drahomir</creatorcontrib><creatorcontrib>BAUMGARTNER, Iris</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SPIRK, David</au><au>UGI, Jörg</au><au>KUCHER, Nils</au><au>KORTE, Wolfgang</au><au>HUSMANN, Marc</au><au>HAYOZ, Daniel</au><au>BALDI, Thomas</au><au>FRAUCHIGER, Beat</au><au>BANYAI, Martin</au><au>AUJESKY, Drahomir</au><au>BAUMGARTNER, Iris</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer: The SWIss Venous ThromboEmbolism Registry (SWIVTER) II</atitle><jtitle>Thrombosis and haemostasis</jtitle><addtitle>Thromb Haemost</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>105</volume><issue>6</issue><spage>962</spage><epage>967</epage><pages>962-967</pages><issn>0340-6245</issn><eissn>2567-689X</eissn><coden>THHADQ</coden><abstract>In patients with acute cancer-associated thrombosis, current consensus guidelines recommend anticoagulation therapy for an indefinite duration or until the cancer is resolved. Among 1,247 patients with acute venous thromboembolism (VTE) enrolled in the prospective Swiss Venous Thromboembolism Registry (SWIVTER) II from 18 hospitals, 315 (25%) had cancer of whom 179 (57%) had metastatic disease, 159 (50%) ongoing or recent chemotherapy, 83 (26%) prior cancer surgery, and 63 (20%) recurrent VTE. Long-term anticoagulation treatment for >12 months was more often planned in patients with versus without cancer (47% vs. 19%; p<0.001), with recurrent cancer-associated versus first cancer-associated VTE (70% vs. 41%; p<0.001), and with metastatic versus non-metastatic cancer (59% vs. 31%; p<0.001). In patients with cancer, recurrent VTE (OR 3.46; 95%CI 1.83-6.53), metastatic disease (OR 3.04; 95%CI 1.86-4.97), and the absence of an acute infection (OR 3.55; 95%CI 1.65-7.65) were independently associated with the intention to maintain anticoagulation for >12 months. In conclusion, long-term anticoagulation treatment for more than 12 months was planned in less than half of the cancer patients with acute VTE. The low rates of long-term anticoagulation in cancer patients with a first episode of VTE and in patients with non-metastatic cancer require particular attention.</abstract><cop>Stuttgart</cop><pub>Schattauer</pub><pmid>21475778</pmid><doi>10.1160/TH11-01-0002</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-6245 |
| ispartof | Thrombosis and haemostasis, 2011-06, Vol.105 (6), p.962-967 |
| issn | 0340-6245 2567-689X |
| language | eng |
| recordid | cdi_crossref_primary_10_1160_TH11_01_0002 |
| source | MEDLINE; Thieme Connect Journals |
| subjects | Acute Disease Adult Aged Aged, 80 and over Anticoagulants - administration & dosage Anticoagulants - adverse effects Biological and medical sciences Blood coagulation. Blood cells Clinical Protocols Disease Progression Fundamental and applied biological sciences. Psychology Hematologic and hematopoietic diseases Heparin, Low-Molecular-Weight - administration & dosage Heparin, Low-Molecular-Weight - adverse effects Humans Medical sciences Molecular and cellular biology Neoplasm Metastasis Neoplasms - complications Neoplasms - drug therapy Neoplasms - physiopathology Neoplasms - surgery Platelet diseases and coagulopathies Recurrence Switzerland Time Factors Venous Thromboembolism - drug therapy Venous Thromboembolism - etiology Venous Thromboembolism - physiopathology Venous Thromboembolism - surgery |
| title | Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer: The SWIss Venous ThromboEmbolism Registry (SWIVTER) II |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T01%3A44%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20anticoagulation%20treatment%20for%20acute%20venous%20thromboembolism%20in%20patients%20with%20and%20without%20cancer:%20The%20SWIss%20Venous%20ThromboEmbolism%20Registry%20(SWIVTER)%20II&rft.jtitle=Thrombosis%20and%20haemostasis&rft.au=SPIRK,%20David&rft.date=2011-06-01&rft.volume=105&rft.issue=6&rft.spage=962&rft.epage=967&rft.pages=962-967&rft.issn=0340-6245&rft.eissn=2567-689X&rft.coden=THHADQ&rft_id=info:doi/10.1160/TH11-01-0002&rft_dat=%3Cpubmed_cross%3E21475778%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/21475778&rfr_iscdi=true |